Centrus Energy Corp vs Zimmer Biomet Holdings Inc — how do they compare? Centrus Energy Corp trades at $186.4 (market cap $3.77B), while Zimmer Biomet Holdings Inc trades at $96.92 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 4.9× Centrus Energy Corp's market cap, and Zimmer Biomet Holdings Inc pays a 0.99% dividend while Centrus Energy Corp pays none. Which is the better fit depends on your goals.
| LEU | ZBH | |
|---|---|---|
Market Cap | $3.77B | $18.55B |
Sector | Energy | Health |
52-Week High | $436.00 | $107.71 |
52-Week Low | $146.61 | $79.58 |
Enterprise Value | $3.08B | $25.61B |
Dividend Yield | — | 0.99% |
Signals from Pluang's Aura AI — not financial advice
Centrus Energy (LEU) trades at $186.93, down 1.27% on the day, with a bullish technical signal from moving averages. The company reported mixed Q2 2026 results, beating earnings estimates but showing margin compression. LEU maintains a strong $4.5 billion backlog and secured significant DOE funding, positioning it as a key player in the domestic nuclear fuel supply chain. Valuation metrics appear elevated with a P/E of 68.23 and P/S of 8.89, reflecting growth expectations in the nuclear energy sector.
The outlook remains positive given government support for nuclear energy and Centrus's strategic position in HALEU production. However, investors face risks from execution challenges, cost pressures, and the capital-intensive nature of enrichment facility expansion. Analyst consensus leans bullish with a $228.50 price target, though the stock's premium valuation requires careful monitoring of operational milestones and margin trends.
ZBH trades at $96.04, down 1.78% today, with a bullish technical signal from moving averages and a consensus analyst price target of $103.56. Recent Q2 2026 earnings beat expectations with EPS of $2.07 versus $2.01 expected, and the company raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23 billion and a net income margin of 8.56%.
The outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and debt levels, with the debt-to-asset ratio rising to 32.57% in 2025. Analyst sentiment is mixed with 40% buy ratings, offering a potential 7.8% upside to the consensus target, though investors should monitor margin trends and debt management.
Trailing returns across standard periods
Latest headlines on both assets
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →